Skip to main content
. 2013 May 16;52(9):1642–1647. doi: 10.1093/rheumatology/ket173

Table 1.

Baseline characteristics and demographic details of all groups

Variable Controls (n = 292) aPL (n = 73) APS (n = 73)
Age, median (IQR) 32 (27–35) 36 (32–40)* 36 (31–39)*
Ethnicity, n (%)
    Caucasian 161 (55.1) 47 (64.4) 38 (52.1)
    Indian subcontinent 20 (6.9) 4 (5.5) 8 (11.0)
    African 87 (29.8) 18 (24.7) 23 (31.5)
    Others 24 (8.2) 4 (5.5) 4 (5.5)
Type of aPL, n (%) NA
    aCL IgGa 11 (15.1) 2 (2.7)
    aCL IgMa 5 (6.8) 2 (2.7)
    LA 47 (64.4) 46 (63.0)
    aCL and LA 14 (19.2) 23 (31.5)
BMI, median (IQR) 24 (22–27) 24 (22–27) 25 (21–29)
Nicotine use, n (%) 32 (11.3) 7 (9.6) 9 (12.3)
ART, n (%) 17 (5.8) 17 (23.3)* 9 (12.3)
Medical comorbidities, n (%)
    Hypertension 8 (2.7) 4 (5.5) 8 (11.0)*
    Renal disease 2 (0.7) 1 (1.4) 3 (4.1)*
    Diabetes—type 1 and type 2 4 (1.4) 0 2 (2.74)
    Minor medical problemsb 62 (21.3) 25 (34.3)* 27 (37.0)*
    No medical comorbidities 216 (74.0) 43 (59.0)* 33 (45.2)*
Previous pregnancy morbidity, n (%)
    None 274 (93.8) 68 (93.2) 0*,**
    Recurrent <10-week miscarriage 3 (1.0) 1 (1.4) 19 (26.0)*,**
    Pregnancy loss at ≥10 weeks 9 (3.1) 5 (6.9) 10 (13.7)*
    Delivery <34 weeks from severe pre-eclampsia 0 0 7 (9.6)*,**
    Delivery <34 weeks from severe placental insufficiency or intrauterine growth restriction 1 (0.3) 0 5 (6.9)*,**
Structural anomalies, n (%)
    Cervical insufficiency 16 (11.0) 15 (20.5)*,** 6 (8.2)
    Structural anomalies of the uterus 17 (11.6) 10 (13.7)* 4 (5.5)
Parity, n (%)
    Nulliparity 173 (59.3) 39 (53.4) 27 (37.0)*,**
Aspirin use, n (%) 18 (6.2) 70 (95.9)* 71 (97.3)*
LMWH use, n (%) 5 (1.7) 47 (64.4)* 59 (80.8)*,**
    LMWH continued throughout pregnancy 1 (20.0) 9 (19.1)* 25 (42.4)*,**

IQR: interquartile range. aaCL > 40 GPL or MPL. bMinor medical problems included thyroid disease, recurrent headache, asthma, etc., medical conditions that were not thought to affect fetal growth and pregnancy outcomes in the long term. *P < 0.05 when comparing either aPL or obstetric APS and controls. **P < 0.05 when comparing aPL and obstetric APS.